Abstract
Vascular dementia (VaD) accounts for 15–20% of all dementia cases. It is a syndrome of acquired cognitive impairment with a complex pathophysiological basis. A novel herbal formulation (Sailuotong; SLT) consisting of Panax ginseng C.A Mey, Ginkgo biloba L and Crocus sativus L extracts was developed to treat VaD. Preclinical animal studies found significant improvements in memory and in pathogenic biochemical parameters. Appropriate safety of SLT was shown in acute and chronic toxicity studies, and early clinical trials of SLT demonstrated enhancements in cognition in VaD patients. A fully powered study with a long intervention period is needed to confirm the efficacy and safety of this novel intervention. A rigorous phase III clinical trial was developed with the aim of recruiting 238 patients diagnosed with mild to moderate probable VaD, or VaD mixed with Alzheimer’s disease (where cerebrovascular disease is the clinical dominant contributor to dementia, abbreviated as CVD+AD). Using a permuted block strategy, participants will be randomly allocated to receive SLT (120 mg bd) or placebo capsules for an intervention period of 52 weeks and will be followed-up for an additional 13 weeks. The primary outcome measures are the Vascular Dementia Assessment Scale-cognitive subscale and Alzheimer’s Disease Cooperative Study-Activities of Daily Living scale. Secondary outcome measures include the Clinician’s Interview Based Impression of Change-Plus, CLOX, EXIT-25, Neuropsychiatric Inventory-Clinician rating scale, and Dementia Quality of Life questionnaire. Safety is assessed through adverse event reports and liver, renal, and coagulation studies. Primary and secondary outcome measures will be compared between treatment and placebo groups, using intention to treat and per protocol analyses. We hypothesise that a 52-week treatment of SLT will be clinically effective and well tolerated in participants with VaD or AD+CVD. This project will provide vital efficacy and safety data for this novel treatment approach to VaD.
Funder
Australia Shineway Technology Pty Ltd
Publisher
Public Library of Science (PLoS)
Reference41 articles.
1. World Health Organization. Global action plan on the public health response to dementia 2017–2025 [Internet]. Geneva: World Health Organisation. 2017 [cited 2020 Jan 03]. Available from: https://www.who.int/mental_health/neurology/dementia/action_plan_2017_2025/en/
2. Australian Bureau of Statistics. Causes of Death, Australia, (cat. no. 3303.0) [Internet]. Canberra: ABS; 2018 [cited 2020 Apr 14]. Available from http://www.abs.gov.au/ausstats.
3. The pathology and pathophysiology of vascular dementia;RN Kalaria;Neuropharmacology,2018
4. Vascular dementia: emerging trends;NT Aggarwal;Seminars in Neurology,2007
5. Person-specific contribution of neuropathologies to cognitive loss in old age;PA Boyle;Ann Neurol,2018
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献